Powell Adam, Torous John
Payer+Provider Syndicate, Boston, MA, United States.
Division of Digital Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
JMIR Ment Health. 2020 Oct 30;7(10):e18812. doi: 10.2196/18812.
As digital health tools such as smartphone apps evolve and enter clinical use, questions regarding their value must be addressed. Although there are scarce generalizable data on the value of health apps given their nascency and diverse use cases, it is possible to estimate the economic value of the clinical improvement they bring to patients using a quality-adjusted life-year (QALY)-based approach and generalized values from existing literature.
This paper aims to provide a patient-centered framework for assessing the economic value of the clinical benefits delivered by digital health apps.
We proposed a model based upon 5 levers: country-specific monetary value of a QALY, QALYs lost due to the condition, engagement rate of app users, average effect size of the app's health impact, and duration of the app's impact before remission.
Using 2 digital health apps from the United States and United Kingdom as examples, we explored how this model could generate country-specific estimates of the economic value of the clinical benefits of health apps.
This new framework can help drive research priorities for digital health by elucidating the factors that influence the economic value.
随着智能手机应用程序等数字健康工具不断发展并进入临床应用,必须解决有关其价值的问题。鉴于健康应用程序尚处于起步阶段且使用案例多样,虽然关于其价值的可推广数据稀缺,但使用基于质量调整生命年(QALY)的方法和现有文献中的通用价值来估计它们给患者带来的临床改善的经济价值是可行的。
本文旨在提供一个以患者为中心的框架,用于评估数字健康应用程序带来的临床益处的经济价值。
我们提出了一个基于五个杠杆的模型:特定国家的QALY货币价值、因该疾病而损失的QALY、应用程序用户的参与率、应用程序对健康影响的平均效应大小以及缓解前应用程序影响的持续时间。
以美国和英国的两款数字健康应用程序为例,我们探讨了该模型如何生成特定国家对健康应用程序临床益处经济价值的估计。
这个新框架可以通过阐明影响经济价值的因素来帮助推动数字健康的研究重点。